# Phase I/IIa Trial of Folate Binding Protein Vaccine in Ovarian Cancer

> **NCT01580696** · PHASE1,PHASE2 · COMPLETED · sponsor: **COL George Peoples, MD, FACS** · enrollment: 51 (actual)

## Conditions studied

- Ovarian Cancer
- Endometrial Cancer
- Fallopian Cancer
- Peritoneal Cancer

## Interventions

- **BIOLOGICAL:** E39 peptide (100mcg)/GM-CSF vaccine plus E39 booster
- **OTHER:** Non-vaccine clinically matched control group
- **BIOLOGICAL:** E39 peptide (500mcg)/GM-CSF vaccine plus E39 booster
- **BIOLOGICAL:** E39 peptide (1000mcg)/GM-CSF vaccine plus E39 booster
- **BIOLOGICAL:** E39 peptide (100mcg)/GM-CSF vaccine plus J65 booster
- **BIOLOGICAL:** E39 peptide (500mcg)/GM-CSF vaccine plus J65 booster
- **BIOLOGICAL:** E39 peptide (1000mcg)/GM-CSF vaccine plus J65 booster

## Key facts

- **NCT ID:** NCT01580696
- **Lead sponsor:** COL George Peoples, MD, FACS
- **Sponsor class:** FED
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2012-04
- **Primary completion:** 2016-07-31
- **Final completion:** 2016-07-31
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2020-05-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01580696

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01580696, "Phase I/IIa Trial of Folate Binding Protein Vaccine in Ovarian Cancer". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01580696. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*